PKO Investment Management Joint Stock Co Acquires Shares of 6,000 Gilead Sciences, Inc. (NASDAQ:GILD)

PKO Investment Management Joint Stock Co bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 6,000 shares of the biopharmaceutical company's stock, valued at approximately $554,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Bridgewater Associates LP grew its stake in Gilead Sciences by 122.7% in the fourth quarter. Bridgewater Associates LP now owns 460,936 shares of the biopharmaceutical company's stock valued at $42,577,000 after purchasing an additional 253,994 shares in the last quarter. McAdam LLC lifted its position in shares of Gilead Sciences by 16.7% during the 4th quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company's stock worth $2,344,000 after purchasing an additional 3,627 shares during the last quarter. Nissay Asset Management Corp Japan ADV increased its position in shares of Gilead Sciences by 5.2% during the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock valued at $26,750,000 after purchasing an additional 14,009 shares during the period. Foster & Motley Inc. raised its stake in shares of Gilead Sciences by 80.4% in the 4th quarter. Foster & Motley Inc. now owns 10,587 shares of the biopharmaceutical company's stock valued at $978,000 after buying an additional 4,718 shares in the last quarter. Finally, Clear Creek Financial Management LLC acquired a new position in shares of Gilead Sciences in the 4th quarter worth approximately $1,173,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

Analyst Ratings Changes

A number of research firms recently commented on GILD. Oppenheimer decreased their price target on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a "hold" rating to a "buy" rating and upped their price objective for the company from $80.00 to $120.00 in a report on Tuesday, February 18th. The Goldman Sachs Group increased their target price on Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research note on Wednesday, February 12th. Morgan Stanley increased their target price on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. Finally, Royal Bank of Canada increased their target price on Gilead Sciences from $84.00 to $90.00 and gave the company a "sector perform" rating in a research note on Wednesday, February 12th. Nine investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, Gilead Sciences has an average rating of "Moderate Buy" and an average price target of $110.55.

Gilead Sciences Stock Down 1.1%

GILD stock traded down $1.17 during mid-day trading on Monday, reaching $108.91. The company had a trading volume of 9,986,911 shares, compared to its average volume of 7,723,878. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The stock has a 50 day simple moving average of $105.49 and a two-hundred day simple moving average of $101.04. The company has a market capitalization of $135.48 billion, a price-to-earnings ratio of 294.35, a PEG ratio of 0.71 and a beta of 0.26. Gilead Sciences, Inc. has a 52 week low of $62.69 and a 52 week high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The company had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same period in the previous year, the company posted ($1.32) EPS. The firm's revenue for the quarter was down .3% compared to the same quarter last year. As a group, equities analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 annualized dividend and a dividend yield of 2.90%. Gilead Sciences's dividend payout ratio is currently 66.53%.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction on Friday, May 30th. The stock was sold at an average price of $110.42, for a total value of $1,104,200.00. Following the completion of the transaction, the chief executive officer now directly owns 620,268 shares of the company's stock, valued at $68,489,992.56. The trade was a 1.59% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the completion of the transaction, the insider now directly owns 121,152 shares of the company's stock, valued at $13,026,263.04. This represents a 18.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 60,929 shares of company stock valued at $6,748,980. Insiders own 0.27% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.